Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 80 clinical trials
featured
Myelofibrosis

Myelofibrosis

  • 532 views
  • 08 Nov, 2020
  • 1 location
IMG-7289 in Patients With Essential Thrombocythemia

This is a Phase 2b open label study of an orally administered LSD1 inhibitor, IMG-7289, in patients with essential thrombocythemia. This study investigates the following:

thrombocytosis
platelet count
thrombosis
interferon
  • 1 views
  • 31 Jul, 2021
  • 6 locations
Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance

This is a Phase 3 open-label, multicenter, randomized, active-controlled study designed to compare the efficacy and safety and tolerability of P1101 compared with ANA after 12 months of treatment as second-line therapy for subjects with ET who have had a suboptimal or failed response to HU.

hydroxyurea
thrombocytosis
neutrophil count
ropeginterferon alfa-2b
thrombosis
  • 0 views
  • 20 Mar, 2021
  • 51 locations
Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Childhood and Adolescent Essential Thrombocythemia

Objectives: To compare the efficacy and safety in childhood and adolescent patients (<20 years) diagnosed as essential thrombocythemia treated with the Pegylated Interferon Alfa-2b vs

  • 1 views
  • 25 Jul, 2021
  • 1 location
Hematology IMG-7289 LSD1 (Lysine-Specific Demethylase 1) Inhibitor Essential Thrombocythemia (ET) Ph 2

This is a single-center, open-label investigator-initiated trial evaluating the effects of IMG-7289 administered orally once daily in patients with essential thrombocythemia.

hydroxyurea
thrombocytosis
neutrophil count
thrombosis
myelofibrosis
  • 0 views
  • 21 Jun, 2021
  • 1 location
Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia

ratio of aspirin maintenance in high risk Essential thrombocythemia (ET) patients, in hematological response (modified by amendment 1/03/2017) on Hydroxyurea.

aspirin
essential thrombocythemia
thrombosis
hydroxyurea
thrombocytosis
  • 1 views
  • 21 Jan, 2021
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis Post Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis

) Condition or disease: Primary Myelofibrosis/Post-Polycythemia Vera Myelofibrosis/ Post-essential Thrombocythemia Myelofibrosis Intervention/treatment: Drug-Pacritinib

ct scan
renal function
thrombocytopenia
thrombocytosis
conjugated bilirubin
  • 506 views
  • 21 Aug, 2021
  • 178 locations
To Assess the Safety Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)

This is a 2-part study. In Part 1, participants will be dosed at 2 different dose levels in order to select the RP2D for Part 2 of the study.

ruxolitinib
myelofibrosis
  • 0 views
  • 08 Aug, 2021
  • 12 locations
Study of CPI-0610 in Myelofibrosis (MF)

A Phase 3, randomized, blinded study comparing CPI-0610 and ruxolitinib with placebo and ruxolitinib in myelofibrosis (MF) patients that have not been exposed previously to Janus kinase inhibitors (JAKi). CPI-0610 is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins. Evidence suggests that inhibition of both BET and JAK …

  • 0 views
  • 19 Sep, 2021
  • 47 locations
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

The purpose of the study is to compare the efficacy of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis.

  • 2 views
  • 19 Sep, 2021
  • 162 locations